Form 4: Regulus Therapeutics Inc. Executive Sells Shares to Cover Tax Obligations

Christopher Aker, Sr. VP & General Counsel of Regulus Therapeutics Inc., sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs) under a pre-existing 10b5-1 plan.

Summary

• On January 13, 2025, Christopher Aker sold 38,547 shares of Regulus Therapeutics Inc. common stock at a price of $1.2632 per share.
• On January 14, 2025, Christopher Aker sold 5,088 shares of Regulus Therapeutics Inc. common stock at a price of $1.2632 per share.
• These sales were executed under a pre-existing 10b5-1 plan to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• The RSUs commenced vesting on January 9, 2025, and January 12, 2024.
• Following these transactions, Christopher Aker beneficially owns 49,546 shares of Regulus Therapeutics Inc. common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock sales to cover tax obligations, which is neither particularly positive nor negative.

Industry Context

Executive stock sales are a common occurrence, especially when tied to pre-arranged plans like 10b5-1 plans, which allow insiders to sell shares without being accused of trading on non-public information. These sales are often related to tax obligations arising from the vesting of stock-based compensation.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the relatively small number of shares sold.

Key Dates